1. Home
  2. III vs MDWD Comparison

III vs MDWD Comparison

Compare III & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Information Services Group Inc.

III

Information Services Group Inc.

N/A

Current Price

$5.74

Market Cap

197.1M

ML Signal

N/A

Logo MediWound Ltd.

MDWD

MediWound Ltd.

N/A

Current Price

$13.60

Market Cap

181.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
III
MDWD
Founded
2006
2000
Country
United States
Israel
Employees
1500
N/A
Industry
Professional Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
197.1M
181.1M
IPO Year
2006
2013

Fundamental Metrics

Financial Performance
Metric
III
MDWD
Price
$5.74
$13.60
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$6.80
★ $30.67
AVG Volume (30 Days)
★ 185.0K
80.8K
Earning Date
11-02-2026
11-19-2026
Dividend Yield
★ 3.25%
N/A
EPS Growth
★ 216.67
N/A
EPS
★ 0.12
N/A
Revenue
★ $192,745,000.00
N/A
Revenue This Year
$4.24
$39.60
Revenue Next Year
$3.59
$34.34
P/E Ratio
$45.00
★ N/A
Revenue Growth
★ 4.51
N/A
52 Week Low
$3.74
$12.52
52 Week High
$6.45
$20.03

Technical Indicators

Market Signals
Indicator
III
MDWD
Relative Strength Index (RSI) 70.83 N/A
Support Level $5.47 N/A
Resistance Level $6.11 N/A
Average True Range (ATR) 0.15 0.00
MACD 0.01 0.00
Stochastic Oscillator 98.06 0.00

Price Performance

Historical Comparison
III
MDWD

About III Information Services Group Inc.

Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: